15 completed, 5 unknown, 4 active not recruiting, 4 recruiting. 30 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 30 | Completed 15, Unknown 5, Active not recruiting 4, Recruiting 4, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Terminated 1 |
Follow Peritoneal Neoplasms: new trials by email Literature Review of Peritoneal Neoplasms trials Research Report on Peritoneal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) - Colorectal Cancer, Gastric Cancers | Phase 2 / Phase 3 | Recruiting | GE Healthcare | 175 | 2026-10-01 | 2026-06-17 |
| Prophylactic PIPAC in Patients With High-risk Colorectal Cancer oxaliplatin-based PIPAC, Control (Standard treatment) - Colorectal Cancer Control and Prevention, Colorectal Cancer | Phase 3 | Not yet recruiting | Jeremy Meyer | 160 | 2026-01-01 | 2025-07-30 |
| Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 148 | 2025-10-24 | 2026-10-05 |
| A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer Sofetabart Mipitecan, Paclitaxel, Topotecan - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 3 | Recruiting | Eli Lilly and Company | 1630 | 2025-10-22 | 2026-10-08 |
| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2, Nab-paclitaxel 100 mg/m^2 - Ovarian Neoplasm, Fallopian Tube Neoplasms | Phase 3 | Active not recruiting | Corcept Therapeutics | 381 | 2022-06-29 | 2026-09-25 |
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) Letrozole 2.5mg, Placebo - Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms | Phase 3 | Recruiting | Swiss GO Trial Group | 540 | 2020-11-05 | 2025-09-29 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Oregovomab, Paclitaxel, Carboplatin - Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 3 | Active not recruiting | CanariaBio Inc. | 615 | 2020-08-25 | 2026-04-01 |
| Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis Radical colectomy, HIPEC, Systemic chemotherapy - Colorectal Cancer | Phase 3 | Unknown | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 688 | 2020-06-04 | 2020-06-16 |
| Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Pembrolizumab, Placebo for pembrolizumab, Carboplatin - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1367 | 2018-12-18 | 2026-08-19 |
| Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. Cytoreductive surgery + Gastrecomy, Hyperthermic Intraperitoneal Chemotherapy (HIPEC) - Stomach Neoplasm, Peritoneal Carcinomatosis | Phase 3 | Active not recruiting | The Netherlands Cancer Institute | 102 | 2017-10-01 | 2025-07-17 |
| Clinical Analysis of HIPEC for T4 Colorectal Cancer After Surgery Surgery and HIPEC with Lobaplatin, Surgery without HIPEC - Colorectal Neoplasms | Phase 3 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 300 | 2017-08-01 | 2017-07-18 |
| Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer HIPEC with neoadjuvant chemotherapy, Systemic chemotherapy - Gastric Cancer, Peritoneal Carcinomatosis | Phase 3 | Unknown | Shu-Zhong Cui | 88 | 2017-08-01 | 2017-06-07 |
| Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis St. John's Wort, Photodynamic diagnostic and therapy - Peritoneal Carcinomatosis | Phase 3 | Unknown | University Hospital Tuebingen | 50 | 2017-07-31 | 2017-10-27 |
| Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases Perioperative systemic therapy, Perioperative CAPOX-bevacizumab, Perioperative FOLFOX-bevacizumab - Colorectal Neoplasm, Colorectal Cancer | Phase 2 / Phase 3 | Active not recruiting | Koen Rovers | 358 | 2017-06-01 | 2026-03-24 |
| A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Paclitaxel, Carboplatin, Atezolizumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | Hoffmann-La Roche | 1301 | 2017-03-08 | 2023-02-17 |
| Adjuvant HIPEC in High Risk Colon Cancer Adjuvant HIPEC (open/laparoscopic), Standard adjuvant systemic chemotherapy, Diagnostic laparoscopy - Colorectal Neoplasms, Peritoneal Neoplasms | Phase 3 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 204 | 2015-03-01 | 2021-09-16 |
| Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis HIPEC - Malignant Neoplasm of Stomach, Secondary Malignant Neoplasm of Peritoneum | Phase 3 | Completed | Charite University, Berlin, Germany | 105 | 2014-03-01 | 2021-07-29 |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Trabectedin, DOXIL, Dexamethasone - Ovarian Neoplasms, Peritoneal Neoplasms | Phase 3 | Completed | Janssen Research & Development, LLC | 581 | 2013-10-16 | 2019-04-01 |
| Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer positive cytology with HIPEC - Gastric Cancer, Peritoneal Carcinomatosis | Phase 2 / Phase 3 | Terminated | University Hospital Tuebingen | 3 | 2012-09-01 | 2018-01-30 |
| Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer HIPEC, No HIPEC - Epithelial Ovarian Cancer | Phase 3 | Unknown | PEDRO VILLAREJO CAMPOS | 60 | 2012-01-01 | 2018-08-21 |
Showing 20 of 30. Sign in to see all of them.
Ovarian Neoplasms (15) · Fallopian Tube Neoplasms (13) · Colorectal Neoplasms (7) · Stomach Neoplasms (6) · Carcinoma, Ovarian Epithelial (4) · Colonic Neoplasms (2) · Genital Neoplasms, Female (2) · Pelvic Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Genital Diseases, Female (1) · Hyperthermia (1) · Intestinal Obstruction (1) · Krukenberg Tumor (1)
Abdominal Neoplasms (30) · Digestive System Diseases (30) · Digestive System Neoplasms (30) · Neoplasms by Site (30) · Peritoneal Diseases (30) · Neoplasms (29) · Adnexal Diseases (16) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Genital Diseases (16) · Urogenital Diseases (16) · Urogenital Neoplasms (16) · Endocrine Gland Neoplasms (15) · Endocrine System Diseases (15) · Genital Diseases, Female (15)
Carboplatin (8) · Hyperthermic Intraperitoneal Chemotherapy (8) · Paclitaxel (7) · Bevacizumab (4) · Gemcitabine (3) · liposomal doxorubicin (3) · Laparoscopy (2) · Neoadjuvant Therapy (2) · Oxaliplatin (2) · 130-nm albumin-bound paclitaxel (1) · Cisplatin (1) · Cytoreduction Surgical Procedures (1) · Dexamethasone (1) · Diathermy (1) · Docetaxel (1)
Eli Lilly and Company (3) · University Hospital Tuebingen (2) · AGO Study Group (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Affiliated Cancer Hospital & Institute of Guangzhou Medical University (1) · Boehringer Ingelheim (1) · CanariaBio Inc. (1) · Charite University, Berlin, Germany (1) · Corcept Therapeutics (1) · ECOG-ACRIN Cancer Research Group (1) · GE Healthcare (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hoffmann-La Roche (1) · Ipsen (1) · Janssen Research & Development, LLC (1)
United States (14) · France (10) · Belgium (9) · Germany (9) · Spain (9) · Australia (8) · Italy (8) · Poland (8) · Canada (6) · Netherlands (6) · United Kingdom (6) · Brazil (5) · China (5) · Czechia (5) · Denmark (5)
Adrian Jubb, MBChB, PhD, FRCPath (1) · Alexandra R Brandt-Kerkhof, MD (1) · Arend G Aalbers, MD (1) · Beate Rau, Prof. (1) · Cary Presant, MD (1) · Cornelis J Punt, MD, PhD (1) · Daniel P Gold, PhD (1) · Eino B van Duyn, MD, PhD (1)
PMID 37407274, PMID 37185961, PMID 22987083, PMID 23109694, PMID 24318743, PMID 26003804, PMID 26590673, PMID 30630885, PMID 31023318, PMID 31060544, PMID 31371228, PMID 31924332, PMID 32717180, PMID 33476595, PMID 33528867, PMID 33891472, PMID 33960681, PMID 34009291, PMID 35524184, PMID 36123540, PMID 36332161, PMID 36595569, PMID 37364223, PMID 37625235, PMID 37906724, PMID 37916797, PMID 37922442, PMID 39032926, PMID 40374989, PMID 40473448, PMID 41974149, PMID 42372745, PMID 42419336, PMID 42705254, PMID 42849725
2016 (2), 2005 (1), 2008 (1), 2009 (1), 2014 (1), 2015 (1), 2018 (1), 2019 (1), 2025 (1), U10CA180820 (1)